Zanamivir

Generic Name: Zanamivir

Brand Names: Relenza, Dectova

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₀N_₄O_₇

CAS Number: 139110-80-8

Unique Ingredient Identifier: L6O3XI777I

Background: A guanido-neuraminic acid that is used to inhibit neuraminidase.

Indication: For the prevention and treatment of influenza A and B.

Associated Conditions: Flu caused by Influenza

Associated Therapies: -

Clinical Trials

Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults

Phase 1

Completed

Conditions: Influenza
Virus Diseases

Interventions: Drug: Zanamivir
Drug: Oseltamivir

First Posted Date: 2009-06-16

Last Posted Date: 2010-03-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 17

Registration Number: NCT00921726

Locations: 🇹🇭
Mathidol University, Salaya, Thailand

Zanamivir Versus Trivalent Split Virus Influenza Vaccine

Phase 3

Completed

Conditions: Influenza

Interventions: Drug: Zanamivir
Biological: Fluviral

First Posted Date: 2008-11-04

Last Posted Date: 2014-11-21

Lead Sponsor: Mount Sinai Hospital, Canada

Target Recruit Count: 64

Registration Number: NCT00784784

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy